AN ECONOMIC EVALUATION OF RANIBIZUMAB VERSUS AFLIBERCEPT FOR THE TREATMENT OF NEOVASCULAR (WET) AMD IN THE UNITED KINGDOM

被引：1
|
作者：
Malcolm, W. A. [1 ]
Claxton, L. [2 ]
Hodgson, R. [3 ]
Taylor, M. [2 ]
机构：
[1] Novartis UK, Frimley, England
[2] Univ York, York Hlth Econ Consortium, York YO10 5DD, N Yorkshire, England
[3] York Hlth Econ Consortium, York, N Yorkshire, England
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 03期
关键词：
D O I：
10.1016/j.jval.2015.03.1057
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSS25
引用
收藏
页码：A183 / A183
页数：1
相关论文
共 50 条
  • [1] Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
    Maria Waizel
    Margarita G. Todorova
    Michael Masyk
    Katharina Wolf
    Annekatrin Rickmann
    Khaled Helaiwa
    Björn R. Blanke
    Peter Szurman
    BMC Ophthalmology, 17
  • [2] Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD
    Waizel, Maria
    Todorova, Margarita G.
    Masyk, Michael
    Wolf, Katharina
    Rickmann, Annekatrin
    Helaiwa, Khaled
    Blanke, Bjoern R.
    Szurman, Peter
    BMC OPHTHALMOLOGY, 2017, 17
  • [3] Ranibizumab for the treatment of neovascular AMD
    Kaiser, P. K.
    Do, D. V.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2007, 61 (03) : 501 - 509
  • [4] Assessing Intraocular Inflammation After Ranibizumab and Aflibercept Injections for Neovascular AMD
    Roth, Daniel B.
    Fine, Howard F.
    Prenner, Jonathan
    Shah, Sumit P.
    Feng, Henry
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [5] Response to Aflibercept After Frequent Re-treatment With Bevacizumab or Ranibizumab in Eyes With Neovascular AMD
    Thorell, Mariana R.
    Nunes, Renata Portella
    Chen, Gene W.
    Doshi, Rishi R.
    Dugar, Jyoti
    George, Mathew K.
    Kim, Brian T.
    Lowrance, Matthew D.
    Modi, Dimple
    Nahas, Zayna
    Gregori, Giovanni
    Yehoshua, Zohar
    Feuer, William
    Rosenfeld, Philip J.
    OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2014, 45 (06): : 526 - 533
  • [6] Clinical efficacy of aflibercept in non responsive to ranibizumab choroidal neovascular lesions in AMD
    Donati, Simone
    Cattaneo, Jennifer
    Bianchi, Marco
    Caprani, Simona Maria
    Gandolfi, Carlo
    Premoli, Laura
    Vinciguerra, Riccardo
    Testa, Francesco
    Azzolini, Claudio
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [7] Evaluation of contrast sensitivity and other visual function outcomes in neovascular AMD patients following treatment switch to aflibercept from ranibizumab
    Nixon, Don
    Flinn, Nicholas
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [8] Aflibercept in refractory wet AMD treated with ranibizumab: Anatomical and visual outcome
    Abou-Ltaif, Sleiman
    SAUDI JOURNAL OF OPHTHALMOLOGY, 2016, 30 (04) : 227 - 232
  • [9] Twelve-month outcomes of aflibercept versus ranibizumab for neovascular age-related macular degeneration (AMD)
    Almuhtaseb, Hussein
    Michaels, Luke
    Vardarinos, Thanos
    Lotery, Andrew J.
    EYE, 2018, 32 (11) : 8 - 10
  • [10] Treatment of Neovascular AMD by Aflibercept (Eylea) with Proreactive protocol
    Gonzalez, Corinne
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
12345